Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + romiplostim
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination therapy consisting of daratumumab, an anti-CD38 monoclonal antibody, and romiplostim, a thrombopoietin receptor agonist. Daratumumab targets CD38-expressing cells including plasma cells that may produce autoantibodies in immune thrombocytopenia (ITP), while romiplostim stimulates platelet production by binding to thrombopoietin receptors on megakaryocyte precursors. This combination potentially addresses both the autoimmune component and platelet production deficiency in refractory ITP.
02
Targets
CD38 (Cluster of Differentiation 38)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on daratumumab + romiplostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + romiplostim.